Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep 15;7(10):6743-51.
eCollection 2014.

Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer

Ho-Cheol Kim  1 , Joon Seon Song  2 , Jae Cheol Lee  3 , Dae Ho Lee  3 , Sang-We Kim  3 , Jung-Shin Lee  3 , Woo Sung Kim  1 , Jin Kyung Rho  4 , Sun Ye Kim  5 , Chang-Min Choi  6
Affiliations

Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer

Ho-Cheol Kim et al. Int J Clin Exp Pathol. .

Abstract

Background: Small cell lung cancer (SCLC) is one of highly aggressive cancers with poor prognosis. Unfortunately, there are as yet no molecular targets that can be exploited to prolong survival in patients with SCLC. This study aimed to investigate possible molecular markers associated with prognosis in limited-stage small cell lung cancer (LS-SCLC).

Methods: The demographic and clinical data for LS-SCLC patients treated in a tertiary care hospital between January 2008 and December 2012 were retrospectively reviewed. NQO1 polymorphism and the expression of p53, SOD2, PARP1 were examined in biopsy specimens, and the factors affecting prognosis were identified.

Results: 79 patients with LS-SCLC having available pathologic tissues were analyzed. 84.8% of them received both chemotherapy and radiotherapy. NQO1 polymorphism was detected in 60.0% (45/79; heterozygous in 26 patients, homozygous in 19 patients). Over-expression of p53, SOD2, PARP1 was seen in 45.6% (36/79), 38.0% (30/79) and 41.8% (33/79) of the patients, respectively. The univariate Cox proportional hazards model revealed that serum lactate dehydrogenase (LDH) levels and PARP1 expression were associated with disease progression. In the multivariate analysis, only PARP1 expression was a significant independent prognostic factor for progression-free survival (hazard ratio: 0.494; 95% CI, 0.267-0.913, P = 0.025).

Conclusions: PARP1 expression is correlated with longer progression-free survival in LS-SCLC requiring further studies to clarify the precise role of PARP1 and the relevance of PARP1-targeted therapy.

Keywords: NQO1 polymorphism; PARP1; Small cell lung cancer; prognosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
NQO1 polymorphism (A) and progression-free survival in 79 patients with LS-SCLC according to NQO1 polymorphism (B). NQO1 gene fragments were amplified (A) and digested with HInf1 endonuclease (B). *insufficient DNA available for analysis; P: positive control (heterozygous NQO1).
Figure 2
Figure 2
Immunohistochemical staining of SCLC specimens. TOP, (A-D) Negative results for NQO1, p53, SOD2 and PARP1. Bottom, (A1-1-D1-1) Positive results for NQO1, p53, SOD2 and PARP1.
Figure 3
Figure 3
Progression-free survival in 79 patients with LD-SCLC according to PARP1.
See this image and copyright information in PMC

References

    1. Stupp R, Monnerat C, Turrisi AT 3rd, Perry MC, Leyvraz S. Small cell lung cancer: state of the art and future perspectives. Lung Cancer. 2004;45:105–117. - PubMed
    1. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J. Clin. Oncol. 2006;24:4539–4544. - PubMed
    1. Chua YJ, Steer C, Yip D. Recent advances in management of small-cell lung cancer. Cancer Treat Rev. 2004;30:521–543. - PubMed
    1. Micke P, Faldum A, Metz T, Beeh KM, Bittinger F, Hengstler JG, Buhl R. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer-what limits limited disease? Lung Cancer. 2002;37:271–276. - PubMed
    1. Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265–271. - PubMed

Publication types

MeSH terms